# Support to Adopt and Retain Technology (StART) CGM: A pilot study to support continuous glucose monitoring in primary care

> **NIH NIH K23** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $192,624

## Abstract

PROJECT SUMMARY/ABSTRACT
Candidate: Kara R. Mizokami-Stout, MD, MSc is an adult endocrinologist and early career investigator focused
on personalized diabetes management to improve health outcomes. Dr. Mizokami-Stout’s long-term career
objective is to become an independent physician-investigator who promotes evidence-based, system-level
changes to prevent diabetic complications and improve diabetes-specific quality-of-life.
Research Context: Continuous glucose monitoring (CGM) improves glycemic control, reduces hypoglycemia
and facilitates personalized care in insulin-requiring type 2 diabetes (T2D). Despite these benefits, only 3% of
eligible T2D patients seen in primary care are utilizing CGM devices and nearly one-third of CGM-users stop
using these devices after six months. A comprehensive evaluation and a coordinated strategy to target key
determinants of CGM adoption and retention is lacking for T2D, particularly in primary care settings where over
90% of patients with T2D receive their diabetes care. Interventions that address determinants at multiple levels
of influence (e.g., patient, provider, health system) are required to achieve such coordinated delivery and improve
effectiveness of CGM in insulin-requiring T2D.
Research Aims: Dr. Mizokami-Stout will utilize Implementation Science (via the Tailored Implementation in
Chronic Diseases checklist) to: (1) develop an in-depth understanding of patient-, provider-, and system-level
barriers and facilitators to CGM use; (2) design an evidence- and theory-based multilevel intervention entitled
Support to Adopt and Retain Technology (StART) CGM that addresses key determinants of CGM adoption and
retention; and (3) evaluate the feasibility, acceptability, and preliminary efficacy of StART CGM to improve CGM
adoption and retention in insulin-requiring T2D in primary care.
Career Development Plan: Dr. Mizokami-Stout will develop expertise in: (1) Implementation Science for
intervention development and evaluation; (2) designing multilevel, tailored interventions utilizing the electronic
health record; and 3) mixed methods evaluation of pragmatic trials. Dr. Mizokami-Stout’s training will be
supported by highly experienced, interdisciplinary mentors; advanced didactic coursework; and participation in
research and career development meetings and seminars within an ideal training environment. An NIDDK K-23
award will allow Dr. Mizokami-Stout to become an independent physician-investigator and national leader in
developing, testing and implementing multilevel interventions to incorporate evidence-based diabetes
technology into routine diabetes care.

## Key facts

- **NIH application ID:** 10894244
- **Project number:** 5K23DK131296-03
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** Kara R Mizokami-Stout
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $192,624
- **Award type:** 5
- **Project period:** 2022-09-15 → 2027-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10894244

## Citation

> US National Institutes of Health, RePORTER application 10894244, Support to Adopt and Retain Technology (StART) CGM: A pilot study to support continuous glucose monitoring in primary care (5K23DK131296-03). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10894244. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*